The comparison of KRAS G12C and G12V with WT KRAS in a panel of 67 non-small cell lung cancer cell lines showed that these mutations decreased AKT activation compared to WT KRAS (Figure 1B) (23). This evidence concerns the gene KRAS and non-small cell lung carcinoma.